POAI
Predictive Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Significant Net Income Decline
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About POAI
Predictive Oncology Inc.
A knowledge-driven company focused on applying artificial intelligence to develop optimal cancer therapies
Healthcare Equipment and Supplies
04/23/2002
08/26/2015
NASDAQ Stock Exchange
23
12-31
Common stock
91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201
--
Predictive Oncology Inc., originally established in Minnesota under the name BioDrain Medical, Inc., was established on April 23, 2002. On August 6, 2013, the company changed its name to Skyline Medical Corporation. The company is a knowledge and science driven company that applies artificial intelligence (" AI ") to support the discovery and development of optimal cancer therapies that can ultimately lead to more effective treatments and improve patient outcomes. The company uses AI and a proprietary biobank of 150,000 + tumor samples, classified by tumor type, to provide actionable insights on drug compounds to improve the drug discovery process and increase the probability of success of drug compounds.
Company Financials
EPS
POAI has released its 2025 Q3 earnings. EPS was reported at -107.25, versus the expected -1.35, missing expectations. The chart below visualizes how POAI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
POAI has released its 2025 Q3 earnings report, with revenue of 3.62K, reflecting a YoY change of -7.40%, and net profit of -77.65M, showing a YoY change of -2409.20%. The Sankey diagram below clearly presents POAI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
